Provided by Tiger Fintech (Singapore) Pte. Ltd.

Abivax S.A.

6.63
-0.1250-1.85%
Volume:52.52K
Turnover:352.95K
Market Cap:420.07M
PE:-2.29
High:7.05
Open:6.80
Low:6.54
Close:6.75
Loading ...

Company Profile

Company Name:
Abivax S.A.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
69
Office Location:
7-11 boulevard Haussmann,Paris,Ile-de-France,France
Zip Code:
75009
Fax:
- -
Introduction:
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Directors

Name
Position
Marc de Garidel
Chief Executive Officer and Director, Chairman of the Board
Carol L. Brosgart
Independent Director
Corinna zur Bonsen Thomas
Independent Director
June Lee
Independent Director
Troy Ignelzi
Independent Director
Kinam Hong
Director
Paolo Rampulla
Director
Philippe Pouletty
Director

Shareholders

Name
Position
Marc de Garidel
Chief Executive Officer and Director, Chairman of the Board
Didier Blondel
Chief Financial Officer and Board Secretary
Didier Scherrer
Chief Scientific Officer
Michael Ferguson
Chief Commercial Officer
Pierre Courteille
Chief Business Officer
Sheldon Sloan
Chief Medical Officer